FDA guidance
Biological Product Deviation Reporting for Blood and Plasma Establishments: Guidance for…
FDA guidance · Final · issued Mar 12, 2020
Key facts
| Title | Biological Product Deviation Reporting for Blood and Plasma Establishments: Guidance for Industry |
|---|---|
| Status | Final |
| Issue date | Mar 12, 2020 |
| Center | Center for Biologics Evaluation and Research |
| Issuing office | Center for Biologics Evaluation and Research |
| Communication type | Guidance Document |
| Regulated product | Biologics |
| Docket number | FDA-2001-D-0007 |
| Open for comment | No |
| Document on fda.gov | fda.gov |
At a glance
- None Product codes referenced
- None Recognized standards referenced
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA guidance documents
FDA guidance documents describe the agency's current thinking on regulatory topics. Drafts are issued for comment before a final version is published.
Source: U.S. Food and Drug Administration (FDA), Guidance Documents